Topics

Akili and Shionogi Announce Strategic Partnership to Develop and Commercialize Digital Therapeutics in Key Asian Markets. $20M upfront ⁦@PureTechH⁩ $PRTC https://www.businesswire.com/news/home/20190306005880/en/Akili-Shionogi-Announce-Strategic-Partne

04:17 EST 7 Mar 2019 | Odi Bruckman

Akili and Shionogi Announce Strategic Partnership to Develop and Commercialize Digital Therapeutics in Key Asian Markets. $20M upfront ⁦ https://www.businesswire.com/news/home/20190306005880/en/Akili-Shionogi-Announce-Strategic-Partnership-Develop-Commercialize …

Original Article: Akili and Shionogi Announce Strategic Partnership to Develop and Commercialize Digital Therapeutics in Key Asian Markets. $20M upfront ⁦@PureTechH⁩ $PRTC https://www.businesswire.com/news/home/20190306005880/en/Akili-Shionogi-Announce-Strategic-Partne

NEXT ARTICLE

More From BioPortfolio on "Akili and Shionogi Announce Strategic Partnership to Develop and Commercialize Digital Therapeutics in Key Asian Markets. $20M upfront ⁦@PureTechH⁩ $PRTC https://www.businesswire.com/news/home/20190306005880/en/Akili-Shionogi-Announce-Strategic-Partne"

Quick Search

Relevant Topic

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...